loading...| Preferred Name | hydromorphone hydrochloride | |
| Synonyms |
Dimorphone Hymorphan Laudicon Novolauden Dilaudid HP Hydrostat Dilaudid |
|
| Definitions |
The hydrochloride salt of the semi-synthetic opioid hydromorphone with analgesic activity. Hydromorphone, the hydrogenated ketone of morphine, selectively binds the mu-opioid receptor, a G protein-coupled receptor. Binding stimulates the exchange of guanosine triphosphate (GTP) for guanosine diphosphate (GDP) on the G-protein complex, resulting in inhibition of plasma membrane-associated adenylate cyclase (AC) and a reduction in intracellular cyclic 3',5'-adenosine monophosphate (cAMP) levels. Due to a reduction in cAMP levels, voltage-gated potassium channels are activated, resulting in neuronal hyperpolarization and a reduction in neuronal excitability. In addition, this agent inhibits the opening of voltage-gated calcium channels, resulting in inhibition of calcium entry into neuronal cells and a reduction in the release of nociceptive neurotransmitters such as substance P and glutamate. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C436" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C436" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000574280 |
|
| altLabel |
Dimorphone Hymorphan Laudicon Novolauden Dilaudid HP Hydrostat Dilaudid |
|
| CAS Registry |
71-68-1 |
|
| cui |
C0023130 C0719907 C1512536 C0700533 C1512537 C0728755 C1512538 C0701971 |
|
| DATE FIRST PUBLISHED |
2007-10-24 |
|
| Date last modified |
2007-10-24 |
|
| definition |
The hydrochloride salt of the semi-synthetic opioid hydromorphone with analgesic activity. Hydromorphone, the hydrogenated ketone of morphine, selectively binds the mu-opioid receptor, a G protein-coupled receptor. Binding stimulates the exchange of guanosine triphosphate (GTP) for guanosine diphosphate (GDP) on the G-protein complex, resulting in inhibition of plasma membrane-associated adenylate cyclase (AC) and a reduction in intracellular cyclic 3',5'-adenosine monophosphate (cAMP) levels. Due to a reduction in cAMP levels, voltage-gated potassium channels are activated, resulting in neuronal hyperpolarization and a reduction in neuronal excitability. In addition, this agent inhibits the opening of voltage-gated calcium channels, resulting in inhibition of calcium entry into neuronal cells and a reduction in the release of nociceptive neurotransmitters such as substance P and glutamate. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C436" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C436" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C436 |
|
| notation |
CDR0000574280 |
|
| NSC Code |
19046 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
hydromorphone hydrochloride |
|
| tui |
T109 T121 |